As reported by Ian Haydock in Scrip News of 19 January 2010, the debate over reforms to Japan's drug reimbursement pricing system is continuing to inch ahead, with signs emerging that the changes could be a double-edged sword for the industry.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilars
News
- FDA approves first eculizumab biosimilar Bkemv for two rare diseases
- EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva
- EMA recommends approval of biosimilar bevacizumab Avzivi
- FDA approves first interchangeable aflibercept biosimilars to treat macular degeneration
Research
- Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
- Tocilizumab and pembrolizumab biosimilar advances for Korean firms
- Unveiling key clinical findings for denosumab biosimilar candidates
- Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
General
- Biosimilars approved in Europe
- Boehringer Ingelheim to expand access to adalimumab biosimilar
- Challenges and progress in the registration of biosimilars in Latin America
- Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia
- MORE EDITORIAL SECTIONS
- Search
Post your comment